GlassScriptPhysician profile
Shahid Zeb
NPI 1952470452
$6,125.55
in general payments reported to CMS, 2019-2025
25 companies · $1,035 in 2025
The $1,035 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $832 · 2020: $721 · 2021: $662 · 2022: $517 · 2023: $862 · 2024: $1,496 · 2025: $1,035.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,373 · Education: $20.03.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,372.86 |
| Education | $20.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,144.60 | 2019-2025 | Rinvoq, Skyrizi, Humira |
| Amgen INC. | $866.23 | 2019-2025 | Krystexxa, Enbrel, Otezla |
| Glaxosmithkline, LLC. | $592.50 | 2019-2025 | Benlysta |
| Pfizer INC. | $285.97 | 2024-2025 | |
| Octapharma USA, INC. | $285.76 | 2021-2025 | Octagam Immune Globulin (Human) |
| Janssen Biotech, INC. | $264.38 | 2019-2025 | Tremfya |
| E.R. Squibb & Sons, L.L.C. | $224.58 | 2019-2025 | Orencia |
| Ucb, INC. | $216.91 | 2019-2025 | Bimzelx, Cimzia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $216.51 | 2019-2023 | |
| Horizon Therapeutics Plc | $201.82 | 2019-2023 | Krystexxa |
| Mallinckrodt Hospital Products INC. | $167.81 | 2020-2021 | |
| Mallinckrodt Enterprises LLC | $152.38 | 2019 | |
| Alexion Pharmaceuticals, INC. | $76.84 | 2020 | |
| Depuy Synthes Sales INC. | $65.24 | 2019-2020 | |
| Ani Pharmaceuticals, INC. | $62.22 | 2023-2025 | Purified Cortrophin Gel |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $56.64 | 2020-2024 | |
| Axsome Therapeutics, INC. | $53.28 | 2023 | Sunosi |
| Radius Health, INC. | $51.08 | 2020-2024 | |
| Novartis Pharmaceuticals Corporation | $40.18 | 2019 | |
| Genentech USA, INC. | $24.25 | 2023 | Actemra |
| Celltrion USA INC. | $20.03 | 2023 | Yuflyma |
| Celgene Corporation | $18.29 | 2019 | |
| Bioventus LLC | $17.41 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $14.35 | 2022 | |
| Organon LLC | $6.29 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shahid Zeb listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.